Literature DB >> 2694422

Indirect activation of blood coagulation in colon cancer.

M Z Wojtukiewicz1, L R Zacharski, V A Memoli, W Kisiel, B J Kudryk, S M Rousseau, D C Stump.   

Abstract

Systemic activation of the coagulation mechanism is known to exist in patients with colon cancer. The mechanism of such activation was investigated using immunohistochemical techniques applied to fresh frozen sections of resected primary colon cancer specimens. Tumor cells stained for tissue factor, factor V, and urokinase-type plasminogen activator. Perivascular and intercellular areas stained for fibrinogen and the "a" subunit of factor XIII. Staining was minimal or absent for protein C, protein S, plasminogen activator inhibitors 1-3, factor VII, factor X, and fibrin (the antigenic site on the amino-terminal portion of B beta chain that is exposed following thrombin cleavage of fibrinopeptide B was not detected). The lack of an intact thrombin-generating pathway in situ associated with viable colon cancer cells is consistent with the findings of others that coagulation activation in colon cancer may be triggered by a soluble tumor product that exerts its effect at sites distant from the tumor. These results may explain the absence of clinical responsiveness of colon cancer to antithrombotic drug therapy and may clarify therapeutic strategies for this common tumor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2694422

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker.

Authors:  M Oya; Y Akiyama; T Yanagida; S Akao; H Ishikawa
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

3.  Identification of human plasma proteins as major clients for the extracellular chaperone clusterin.

Authors:  Amy R Wyatt; Mark R Wilson
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

4.  Trousseau's syndrome.

Authors:  N Callander; S I Rapaport
Journal:  West J Med       Date:  1993-04

5.  The first international urokinase/warfarin trial in colorectal cancer.

Authors:  L Daly
Journal:  Clin Exp Metastasis       Date:  1991 Jan-Feb       Impact factor: 5.150

6.  Acute phase proteins are major clients for the chaperone action of α₂-macroglobulin in human plasma.

Authors:  Amy R Wyatt; Nathan W Zammit; Mark R Wilson
Journal:  Cell Stress Chaperones       Date:  2012-08-16       Impact factor: 3.667

Review 7.  Clinical trials with anticoagulant and antiplatelet therapies.

Authors:  L R Zacharski; K R Meehan; S M Algarra; F A Calvo
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 8.  Tissue factor as a tumor procoagulant.

Authors:  L V Rao
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 9.  The role of fibrin in tumor metastasis.

Authors:  V Costantini; L R Zacharski
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

10.  Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.

Authors:  T Ueno; M Toi; M Koike; S Nakamura; T Tominaga
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.